Skip to main content

Oral methotrexate for recurrent brain tumors in children: a Pediatric Oncology Group study.

Publication ,  Journal Article
Mulne, AF; Ducore, JM; Elterman, RD; Friedman, HS; Krischer, JP; Kun, LE; Shuster, JJ; Kadota, RP
Published in: J Pediatr Hematol Oncol
2000

PURPOSE: Children with recurrent or progressive central nervous system (CNS) tumors have an unfavorable prognosis. Based on Pediatric Oncology Group (POG) institutional pilot data, low-dose oral methotrexate (MTX) was studied. METHODS: Eight dosages of MTX 7.5 mg/m2 every 6 hours were administered on a weekly schedule for as long as 18 months. Patients in six different brain tumor strata were accrued. RESULTS: The response rates (complete or partial responses) were as follows: astrocytoma 2 of 10, malignant glioma 1 of 19, medulloblastoma 0 of 18, brainstem tumor 0 of 12, ependymoma 1 of 7, and miscellaneous histologic types 0 of 12. The main toxicities, mucositis, myelosuppression, and hepatic transaminase elevation were considered tolerable. CONCLUSION: Low-dose oral MTX showed no significant activity against malignant glioma, medulloblastoma, brainstem tumors, and miscellaneous histologic types. Indeterminate but low response rates were observed in children with astrocytoma and ependymoma. This regimen will not be recommended for front-line therapy.

Duke Scholars

Published In

J Pediatr Hematol Oncol

DOI

ISSN

1077-4114

Publication Date

2000

Volume

22

Issue

1

Start / End Page

41 / 44

Location

United States

Related Subject Headings

  • Oncology & Carcinogenesis
  • Neoplasm Recurrence, Local
  • Methotrexate
  • Infant, Newborn
  • Infant
  • Humans
  • Child, Preschool
  • Child
  • Brain Neoplasms
  • Antimetabolites, Antineoplastic
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Mulne, A. F., Ducore, J. M., Elterman, R. D., Friedman, H. S., Krischer, J. P., Kun, L. E., … Kadota, R. P. (2000). Oral methotrexate for recurrent brain tumors in children: a Pediatric Oncology Group study. J Pediatr Hematol Oncol, 22(1), 41–44. https://doi.org/10.1097/00043426-200001000-00008
Mulne, A. F., J. M. Ducore, R. D. Elterman, H. S. Friedman, J. P. Krischer, L. E. Kun, J. J. Shuster, and R. P. Kadota. “Oral methotrexate for recurrent brain tumors in children: a Pediatric Oncology Group study.J Pediatr Hematol Oncol 22, no. 1 (2000): 41–44. https://doi.org/10.1097/00043426-200001000-00008.
Mulne AF, Ducore JM, Elterman RD, Friedman HS, Krischer JP, Kun LE, et al. Oral methotrexate for recurrent brain tumors in children: a Pediatric Oncology Group study. J Pediatr Hematol Oncol. 2000;22(1):41–4.
Mulne, A. F., et al. “Oral methotrexate for recurrent brain tumors in children: a Pediatric Oncology Group study.J Pediatr Hematol Oncol, vol. 22, no. 1, 2000, pp. 41–44. Pubmed, doi:10.1097/00043426-200001000-00008.
Mulne AF, Ducore JM, Elterman RD, Friedman HS, Krischer JP, Kun LE, Shuster JJ, Kadota RP. Oral methotrexate for recurrent brain tumors in children: a Pediatric Oncology Group study. J Pediatr Hematol Oncol. 2000;22(1):41–44.

Published In

J Pediatr Hematol Oncol

DOI

ISSN

1077-4114

Publication Date

2000

Volume

22

Issue

1

Start / End Page

41 / 44

Location

United States

Related Subject Headings

  • Oncology & Carcinogenesis
  • Neoplasm Recurrence, Local
  • Methotrexate
  • Infant, Newborn
  • Infant
  • Humans
  • Child, Preschool
  • Child
  • Brain Neoplasms
  • Antimetabolites, Antineoplastic